The Latest Breaking News from Intellia Therapeutics

Cathie Wood recently acquired shares of the biotech company. Should you do the same?

Intellia Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Intellia Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

These biotech companies’ strategic advancements are setting them up for long-term success.

Promising clinical trial results have analysts optimistic about the company’s future.

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

The technology is literally 'cutting' edge.

Cathie Wood's ARK Innovation ETF isn't afraid to go against Wall Street and the S&P 500. But in some cases, the consensus agrees with the famed ETF manager.

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.